Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Grant J, Afra K. Point-counterpoint: The MERINO trial and what it should imply for future treatment of ESBL bacteremia. J Assoc Med Microbiol Infect Dis Can 2019;4:125-130. [PMID: 36340651 PMCID: PMC9603027 DOI: 10.3138/jammi.2019-0012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Accepted: 07/29/2019] [Indexed: 06/16/2023]

For:	Grant J, Afra K. Point-counterpoint: The MERINO trial and what it should imply for future treatment of ESBL bacteremia. J Assoc Med Microbiol Infect Dis Can 2019;4:125-130. [PMID: 36340651 PMCID: PMC9603027 DOI: 10.3138/jammi.2019-0012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Accepted: 07/29/2019] [Indexed: 06/16/2023]

Number

Cited by Other Article(s)

Gueneau R, Henry B. Which trial do we need? Piperacillin-tazobactam compared with a carbapenem for treatment of graft pyelonephritis caused by extended spectrum β-lactamase-producing Enterobacteriaceae. Clin Microbiol Infect 2023;29:823-825. [PMID: 36958687 DOI: 10.1016/j.cmi.2023.03.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2022] [Revised: 03/08/2023] [Accepted: 03/15/2023] [Indexed: 03/25/2023]